The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma

The ABC-HCC trial is a Phase IIIb, randomised, multicenter, open-label study designed to evaluate the safety and efficacy of atezolizumab plus bevacizumab versus TACE in patients with intermediate-stage HCC. Approximately 434 patients in two arms of treatment will be enrolled.

Trial Details

NCT ID
NCT04803994
Phase
PHASE3
Sponsor
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Status
RECRUITING
Cancer Type
Hepatocellular Carcinoma (HCC) Liver Cancer
Interventions
  • Atezolizumab
  • Bevacizumab
  • TACE
Locations (sample)
  • Graz, Austria|47.06733,15.44197
  • Innsbruck, Austria|47.26266,11.39454
  • Klagenfurt, Austria|46.62472,14.30528
  • Linz, Austria|48.30639,14.28611
  • Sankt Pölten, Austria|48.20762,15.63725

Key Eligibility Criteria

  • Signed Informed Consent Form available
  • Patients\* ≥ 18 years of age at time of signing Informed Consent Form
  • Confirmed hepatocellular carcinoma diagnosis based on histopathological findings from tumor tissue or typical diagnostic imaging on dynamic CT or M…
  • Intermediate stage HCC as defined by the following criteria:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Hepatocellular Carcinoma (HCC) Liver Cancer Trials on Trialify →